A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Huajun Chen, Yi‐Long Wu, Guowu Wu et al.|Journal of Hematology & Oncology|2025Cited by 9
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Huajun Chen, Yi‐Long Wu, Hai‐Yan Tu et al.|Research Square|2024Cited by 0